lungsAn inhaled drug for the treatment of Parkinson’s disease has shown positive results in a Phase I clinical trial, US-based Civitas Therapeutics has announced.

The study showed that CVT-301, an inhaled formulation of levodopa (L-dopa) for the rapid relief from motor fluctuations, is safe and easily absorbed into the bloodstream, via the lungs, at levels that are likely to produce a therapeutic outcome.

Civitas plans to present comprehensive data from the Phase I study at a future scientific meeting.

Civitas co-founder and chief medical officer Martin Freed said that due to the unpredictability of oral L-dopa, the therapeutic rationale for using inhaled L-dopa to manage motor fluctuations in Parkinson’s disease was intuitive but, until now, technically impractical.

"The Phase I data demonstrated the transformative potential of CVT-301 to enable patients to better manage their motor symptoms in light of the extensive clinical experience correlating L-dopa plasma levels to symptomatic relief documented over the past 40 years," said Freed.

Civitas chief scientific officer Dr Richard Batycky added, "As expected, the tolerability of CVT-301 and L-dopa pharmacokinetic profile behaved consistently with the other molecules we have taken into the clinic over the last decade.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Our technology’s proven unique ability to deliver a large, precise dose with an immediate onset should enable Parkinson’s patients to abort ‘off’ episodes and thereby helping to avoid debilitating disruptions in their lives," he said.

Image caption: CVT-301 is able to be absorbed into the bloodstream via the lungs ( Image by Renjith Krishnan).